Last week, biopharmaceutical PDL BioPharma (NASDAQ:PDLI) announced its third-quarter results -- and on the surface, everything looked good. Revenues were up 44% to $111 million due to strong 64% royalty growth to $43 million. Net loss decreased significantly to approximately $7 million for the quarter. Gross margins were a healthy 81% (not including one-time revenue gains), and revenues for the full year 2006 are expected to be in the range of $405 million to $420 million, a 44% increase over 2005.

PDL had a small setback this quarter with its pipeline when its partner, Roche, decided to discontinue the co-development of Daclizumab for asthma. This put a one-time $19 million gain on PDL's income statement, which was responsible for about $0.16 of the $0.23 a share in non-GAAP profits for the company this quarter.

One thing I don't really like is how PDL accounted for that $0.23 a share. This quarter, PDL excluded one-time expenses associated with its acquisition of a drug from Roche, yet accounted for a one-time gain in its non-GAAP earnings resulting from no more need to defer the aforementioned revenue associated with the Roche asthma collaboration. It's no problem if a company is going to exclude one-time items for its non-GAAP results, but it should exclude not only one-time expenses but one-time gains as well -- if it wants to be fair and avoid giving the appearance of massaging perceptions.

I'm probably making too big a deal over this one item, and to be fair, one of the first things mentioned on the conference call was the fact that the recognition of the Roche revenues was a one-time item. Sometimes, though, what the perceptions of a company's actions say about how it's being managed is more important than the actions' reflection on the company's financial results.

I'll give PDL a pass this time, but it's important that management teams of biopharmaceutical companies don't get in the habit of exaggerating or overpromising on their results or timelines. PDL has had a habit of being over-optimistic on its development timelines and underestimating costs multiple times in the past several years, most recently extending the Nuvion and Ularitide development timelines.

In the long run, I really like PDL's pipeline and prospects, but it's tough to invest in a biopharmaceutical company and estimate its fair value when the timelines for its drugs in development are constantly being pushed back significantly. Maybe a little more conservatism is in order for PDL's management in all areas of the company's performance, as it's much better to underpromise and over-deliver than to do the reverse.

PDL is a Motley Fool Rule Breakers recommendation. Which other stocks have David Gardner and his team picked as poised for remarkable growth? Take a free 30-day trial of Rule Breakers and find out.

Fool contributor Brian Lawler does not own shares of any company mentioned in this article. The Fool has a disclosure policy .